Israeli - Kiingereza - Ministry of Health

kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

gp-pharm, s.a. - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

abbvie limited - leuprorelin acetate 5 mg/ml - solution for injection - 5 mg/ml - active: leuprorelin acetate 5 mg/ml excipient: benzyl alcohol glacial acetic acid sodium chloride sodium hydroxide water for injection - lucrin (leuprorelin acetate) is indicated · in metastatic prostate cancer · in locally advanced prostate cancer, as an alternative to surgical castration · as an adjuvant treatment to radiotherapy in patients with high-risk localized or locally advanced prostate cancer · as an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

rowex ltd - leuprorelin acetate - implant - 3 mg, 5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Kanada - Kiingereza - Health Canada

novopharm limited - leuprolide acetate - liquid - 5mg - leuprolide acetate 5mg - antineoplastic agents

Kanada - Kiingereza - Health Canada

verity pharmaceuticals inc. - leuprolide acetate - powder for suspension, sustained-release - 3.75mg - leuprolide acetate 3.75mg - antineoplastic agents

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - in the palliative treatment of metastatic or locally extensive prostatic cancer. (stage c and d).

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: gelatin; mannitol; polyglactin - lucrin depot 7.5 mg injection and lucrin depot 3 month 22.5mg injection and lucrin depot 4 month 30mg injection are indicated in the palliative treatment of metastatic or locally extensive prostatic cancer (stage c and d).

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

takeda products ireland ltd - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection in pre-filled syringe - 11.25 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

takeda products ireland ltd - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection in pre-filled syringe - 30 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin